Avanir to test Nuedexta components for central neuropathic pain in MS
This article was originally published in Scrip
Executive Summary
Avanir Pharmaceuticals has filed an IND with the US FDA to begin a Phase II clinical study for the investigational drug composed of components of its already approved drug Nuedexta (dextromethorphan plus quinidine sulfate), for the treatment of central neuropathic pain in patients with multiple sclerosis.